18/19F-labelled compounds which target the prostate specific membrane antigen
US10882871B2 · kind B2 · utility
2Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 10, 2017 |
| Grant date | Jan 5, 2021 |
| Priority date | — |
| Expiry date | Jan 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.